Literature DB >> 11148243

Mycophenolate mofetil for myasthenia gravis: an open-label pilot study.

E Ciafaloni1, J M Massey, B Tucker-Lipscomb, D B Sanders.   

Abstract

In an open-label study, 12 patients with refractory MG or who were taking only corticosteroids and required additional immunosuppression received mycophenolate mofetil 1 g twice daily for 6 months. A reduction of three points in a quantified MG score and two points in a manual muscle test or a reduction of 50% in corticosteroid dose defined efficacy. Eight patients improved, beginning after 2 weeks to 2 months. No major side effects were observed.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11148243     DOI： 10.1212/wnl.56.1.97

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  31 in total

Review 1.  Treatment of myasthenia gravis.

Authors:  Vikas Kumar; Henry J Kaminski
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing-remitting multiple sclerosis (TIME MS).

Authors:  Gina M Remington; Katherine Treadaway; Teresa Frohman; Amber Salter; Olaf Stüve; Michael K Racke; Kathleen Hawker; Federica Agosta; Maria Pia Sormani; Massimo Filippi; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

3.  A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis.

Authors:  Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov
Journal:  Ther Adv Neurol Disord       Date:  2010-01       Impact factor: 6.570

4.  Two strikes against mycophenolate mofetil therapy for myasthenia gravis.

Authors:  Michio Hirano
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

5.  When do we judge IVIg for myasthenia gravis ineffective?

Authors:  Tsubasa Takizawa; Shigeaki Suzuki; Norihiro Suzuki
Journal:  Neurol Sci       Date:  2014-12-16       Impact factor: 3.307

6.  Leflunomide treatment in corticosteroid-dependent myasthenia gravis: an open-label pilot study.

Authors:  Pei Chen; Huiyu Feng; Juan Deng; Yufei Luo; Li Qiu; Changyi Ou; Weibin Liu
Journal:  J Neurol       Date:  2015-10-29       Impact factor: 4.849

7.  Mycophenolate mofetil as second line immunosuppressant in Myasthenia gravis--a long-term prospective open-label study.

Authors:  F Hanisch; M Wendt; S Zierz
Journal:  Eur J Med Res       Date:  2009-08-12       Impact factor: 2.175

8.  Mycophenolate mofetil for ocular myasthenia.

Authors:  Jane W Chan
Journal:  J Neurol       Date:  2008-02-29       Impact factor: 4.849

Review 9.  Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity.

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Lancet Neurol       Date:  2009-05       Impact factor: 44.182

10.  Mycophenolate mofetil for myasthenia gravis: a clear and present controversy.

Authors:  Chad Heatwole; Emma Ciafaloni
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.